Skip to main content
  • Novel RDN Device Reduces Antihypertensive Drug Need, but Produces Similar BP Drop vs. Sham Procedure – SMART Trial

    A novel device that employs renal mapping and selective renal denervation (msRDN) was safe, and while it did not reduce blood pressure (BP) more than a sham procedure, the new device did reduce antihypertensive medication burden for patients with uncontrolled hypertension, a new study demonstrates.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details